Guardant Health, Inc. research snapshot
GH AI stock analysis sees Guardant Health as a fast-growing liquid-biopsy company whose Shield colorectal-cancer screening launch is becoming a material growth driver. Second-quarter 2026 revenue rose 44% to $335.0 million, with Shield revenue jumping to $52.9 million on about 66,000 tests, yet the company still reported a $120.1 million GAAP net loss and a $69.5 million free-cash-flow outflow. Management raised 2026 revenue guidance to $1.34 billion to $1.36 billion after a UnitedHealth coverage win and inclusion of Shield in American Cancer Society screening guidelines. At the $161.99 July 31 close and about $21.74 billion calculated equity value, the GH AI stock forecast depends on Shield adoption, reimbursement, oncology growth, cash discipline, and a credible route to profitability. This is scenario analysis for information only, not investment advice.
Current price
$161.99 close on July 31, 2026
Market cap
$21.74 billion calculated equity value
AI score
72 / 100
Rating
High-growth precision-oncology and screening platform with improving commercial momentum and a still-unproven path to durable profitability
Trend status
Strong advance above the 50-day and 200-day averages after a Q2 beat and raised guidance, with high event and valuation risk
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Guardant sells blood-based oncology testing (therapy selection and MRD), colorectal-cancer screening, and biopharma data services, linking clinical testing volume to a recurring precision-medicine workflow with an improving gross margin. | High |
| Moat | Clinical evidence, FDA approvals, ACS and NCCN guideline inclusion, payer coverage, laboratory operations, physician relationships, and accumulated molecular data create barriers, but larger diagnostics firms and other liquid-biopsy specialists compete for the same workflows. | Medium |
| Management | Management has expanded Shield and oncology commercialization, raised 2026 guidance twice, and secured major coverage and FDA milestones, but must prove that higher selling and marketing spending converts into durable unit economics and breakeven. | Medium |
| Financial trend | FY2025 revenue grew 33% to $982.0 million. Q2 2026 revenue grew 44% to $335.0 million with a 67% non-GAAP gross margin; GAAP losses and negative free cash flow continue but are narrowing relative to revenue. | High |
| Valuation | At about $21.74 billion of equity value and 18.37x trailing sales, GH is valued on future scale rather than current profits. Negative EPS and free cash flow make P/E-based valuation unsuitable today. | High |
| Technical trend | The July 31 close of $161.99 was above the reported 50-day average of $142.11 and 200-day average of $107.31, near the $176.58 52-week high. RSI of 61.87 signals strong but extended momentum. | Medium-high |
| Risk level | High. Reimbursement and ADLT delays, payer adoption ramp, clinical or regulatory setbacks, competition, rising commercialization costs, ongoing losses, dilution, and a sharp multiple reset can all affect the thesis. | High |
| AI confidence | Reported data are current and well documented, but forecast outcomes hinge on uncertain clinical adoption, payer behavior, ADLT timing, and the pace of operating leverage. | High data confidence |
| Investment certainty | GH is not a high-certainty value setup because its current valuation requires continued exceptional execution before profitability is established. | Medium |
GH AI stock forecast
The GH AI stock forecast uses operating scenarios rather than a P/E model because Guardant has negative EPS and negative free cash flow. The required three-scenario P/E calculation was run with negative EPS and correctly produced non-economic negative values. The ranges below therefore reflect valuation sensitivity to revenue growth, screening adoption, reimbursement, gross margin, cash burn, dilution, and the timeline to profitability. They are scenarios, not price promises.
$195 to $240
More likely if Shield volumes and reimbursement expand faster than guidance after UnitedHealth coverage becomes effective in August and additional payers follow, 2026 revenue exceeds the $1.36 billion top of guidance, Guardant360 Liquid CDx ADLT pricing materializes in 2027, gross margin holds, cash burn narrows, and investors continue to pay a premium for the screening opportunity.
$145 to $190
More likely if revenue meets the $1.34 billion to $1.36 billion guide, Shield adoption grows but commercial spending remains high, oncology and biopharma growth stay healthy, and the market waits for clearer evidence of operating leverage and progress toward 2027 breakeven.
$85 to $125
More likely if payer coverage or primary-care adoption disappoints, the UnitedHealth ramp or ADLT reimbursement weakens, clinical evidence or guideline momentum stalls, expenses remain elevated, cash burn worsens, dilution occurs from the mixed-securities shelf, competitors gain share, or the sales multiple compresses.
GH AI technical analysis
GH AI technical analysis uses StockAnalysis market data available at the August 2, 2026 cutoff. The July 31 close was $161.99, above reported 50-day and 200-day moving averages of $142.11 and $107.31, and near the $176.58 52-week high. This static page does not fetch request-time chart data, so confirm price, volume, moving averages, and momentum in a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $161.99 | July 31, 2026 close used for the market-cap verification. |
| Near support | $150 to $155 | A recent round-number monitoring area below the close, not a guaranteed floor. |
| Trend support | Near $142.11 | Reported 50-day moving average. A sustained move below it would weaken the medium-term trend. |
| Major support | Near $107.31 | Reported 200-day moving average. A sustained break would materially change the longer-term trend view. |
| Near resistance | $170 to $177 | The zone approaching the 52-week high of $176.58, not a prediction of a breakout. |
| Moving averages | 50-day $142.11, 200-day $107.31 | StockAnalysis values available around the cutoff and subject to change with each session. |
| Momentum | RSI 61.87 | Momentum was positive and near the higher end of neutral; RSI alone is not a buy or sell signal. |
| Volume | About 2.20 million average shares over 20 days | Breakouts and breakdowns deserve more weight when volume is above the recent average. |
| Volatility | High | Beta of 1.59 and event-driven moves from earnings, payer news, regulatory events, and clinical data make GH volatile. |
| Invalidation | Sustained close below $142.11 | A confirmed loss of the 50-day trend reference should trigger a review of price action and the underlying commercial thesis. |
GH AI trading strategy
The GH AI trading strategy is a rules-based research framework, not personalized advice. It combines live chart confirmation with Shield test volumes, reimbursement and ADLT updates, revenue growth, gross margin, cash burn, and risk controls.
Watch whether GH holds the $150 to $155 area and clears the $170 to $177 resistance zone on improving volume while the next results support Shield volumes, oncology growth, gross margin, and guidance.
A failed breakout or sustained close below the 50-day average near $142.11 should invalidate a trend setup before losses become open-ended.
If GH pulls back toward the 50-day average without deterioration in reimbursement, Shield test volumes, oncology volumes, guidance, or liquidity, compare the revised sales multiple with the operating path to profitability.
Do not average down solely because the price falls. Reassess if payer access, ADLT timing, clinical evidence, pricing, gross margin, cash burn, or financing needs deteriorate.
Track oncology, screening, and biopharma revenue; Shield test volumes and payer coverage (UnitedHealth, USPSTF progress); reimbursement and ADLT; gross margin; operating expenses; free cash flow; cash and debt; share count; and regulatory or clinical updates.
Position sizing should reflect that a fast-growing diagnostics narrative is not the same as proven, self-funding profitability.
Investment research summary
Customers pay Guardant for blood-based cancer tests that inform treatment decisions (Guardant360 Liquid CDx), monitor recurrence and therapy response (Reveal), support screening (Shield), and provide molecular data and companion diagnostics to biopharma companies.
The moat rests on clinical validation, FDA approvals, ACS and NCCN guideline inclusion, payer coverage, regulatory and reimbursement infrastructure, laboratory operations, relationships with clinicians and biopharma customers, and molecular data accumulated through testing. It can narrow if competing tests match clinical utility or payer access.
The thesis can fail if Shield adoption is slower or less reimbursed than expected, the UnitedHealth ramp disappoints, ADLT pricing or clinical outcomes disappoint, competition intensifies, commercial costs stay high, operating losses persist, funding needs dilute shareholders, or a premium sales multiple contracts after a 258% 52-week gain.
Management is being tested on its ability to scale screening and oncology without allowing sales and marketing investment, laboratory capacity, and operating expenses to outrun gross-profit growth and liquidity, while delivering on its stated 2027 cash-flow breakeven goal.
Precision oncology and blood-based screening address a long-term need for earlier detection and more targeted treatment, with Shield now validated for multiple cancer types. The opportunity is large, but adoption is governed by clinical evidence, guidelines, regulation, reimbursement, physician workflow, and patient access rather than technology alone.
At $161.99, the market is valuing future screening scale, ADLT pricing upside, and operating leverage, not present earnings. Margin of safety would depend on a lower price while reimbursement, test-volume growth, gross margin, liquidity, and the route to profitability remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GH quote and market capitalization | $161.99 close on July 31, 2026; $21.74 billion market capitalization and 134.20 million shares outstanding | StockAnalysis statistics | August 2, 2026 |
| Market-cap verification | $21.74 billion calculated from $161.99 price and 134.20 million shares, with 0.00% variance to the reported value | StockAnalysis and financial_rigor.py market-cap verification | August 2, 2026 |
| Q2 2026 results | $335.0 million revenue, up 44%; oncology revenue $219.1 million, up 38%, on roughly 104,000 tests, up 63%; biopharma and data revenue $60.9 million, up 9%; screening revenue $52.9 million on about 66,000 Shield tests | Guardant Health Q2 2026 press release | August 2, 2026 |
| Q2 2026 margins, losses, and cash flow | GAAP gross margin 65% and non-GAAP gross margin 67%; GAAP net loss $120.1 million (EPS -$0.90); adjusted EBITDA loss $55.9 million; free cash flow -$69.5 million | Guardant Health Q2 2026 press release | August 2, 2026 |
| 2026 guidance raised | Revenue guidance raised to $1.34 billion to $1.36 billion (36% to 38% growth); screening revenue guidance $218 million to $230 million on 270,000 to 285,000 Shield tests; non-GAAP gross margin 64% to 65%; non-GAAP operating expenses $1.08 billion to $1.10 billion; free-cash-flow burn $195 million to $205 million | Guardant Health Q2 2026 press release | August 2, 2026 |
| Liquidity and capital structure | Cash, cash equivalents, and restricted cash of $1.2 billion at June 30, 2026; balance sheet cash and equivalents of $1,053 million, restricted cash of $114 million, and convertible senior notes of $1,503 million | Guardant Health Q2 2026 press release and StockAnalysis balance sheet | August 2, 2026 |
| FY2025 revenue and net income cross-check | $982.0 million revenue and about $416 million GAAP net loss, cross-validated against Guardant Health, StockAnalysis, and Macrotrends | StockAnalysis financials and Macrotrends net-income history | August 2, 2026 |
| TTM revenue and segment mix | TTM revenue of $1.18 billion, including about $798 million oncology, $223 million biopharma and data, and $154 million screening revenue | StockAnalysis financials | August 2, 2026 |
| Technical references | 50-day average $142.11, 200-day average $107.31, RSI 61.87, 52-week high $176.58, and 20-day average volume 2,203,401 shares | StockAnalysis statistics | August 2, 2026 |
| Valuation math | 18.37x trailing sales; forward sales multiple near 16x based on 2026 guidance midpoint; P/E and P/FCF are not meaningful with negative earnings and free cash flow | StockAnalysis and financial_rigor.py valuation verification | August 2, 2026 |
| Analyst consensus | Strong Buy consensus from 25 analysts with a $187.50 average 12-month price target | StockAnalysis forecast | August 2, 2026 |
This page is an informational research tool, not investment advice or a recommendation to buy or sell any security. Forecasts are scenarios based on available data and assumptions, may be wrong, and should be checked against current filings, prices, and professional advice before any decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
